Partnership leverages their individual strengths to achieve high quality, reliable drug product manufacturing. February 25, 2020 – Argonaut Manufacturing Services, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, and
DURHAM, February 24, 2020 — BioSkryb, Inc., a developer of genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing, today announced that it is partnering with Argonaut
Comparing competing proposals is the final step in selecting your biotech contract manufacturing organization (CMO). While it may sound straightforward, due to a lack of industry standardization proposals can vary significantly
Most research and development teams seeking to construct ambient products will encounter the challenges of protein lyophilization. A primary obstacle is enzyme and antibody instability outside of native conditions, as
New introduction supports industry shortage of high-yield filling service providers CARLSBAD, CA – Argonaut Manufacturing Services, a premier contract development and manufacturing organization (CDMO) for biopharma, has announced the recent
As point-of-care (POC) diagnostics and high throughput sequencing expand in popularity, the need for room temperature-stable products grows. POC diagnostics need to be capable of ambient storage in order to
With API (active pharmaceutical ingredient) values continuing to climb as production scales conversely drop, it is time to rethink our aseptic filling processes to minimize API loss. The rise in
Mark O’Donnell Joins Argonaut Manufacturing Services Board Carlsbad, CA, Nov 05, 2019 – Argonaut Manufacturing Services announced today that Mark O’Donnell has been appointed to the company’s Board of Directors.
Every journey to contract manufacturing is unique. Some biotech companies know, at the start, they want to work with a contract manufacturing organization (CMO), while others choose to engage a
Every biopharma company is eventually faced with the “make versus buy” decision – should they fill/finish their drug product in-house or outsource? Complicating things further, a third option also exists